{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T04:54:40Z","timestamp":1761972880508,"version":"build-2065373602"},"reference-count":28,"publisher":"The Society for Free Radical Research Japan","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Biochem. Nutr."],"published-print":{"date-parts":[[2025]]},"DOI":"10.3164\/jcbn.25-49","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T22:07:28Z","timestamp":1753222048000},"page":"240-248","source":"Crossref","is-referenced-by-count":0,"title":["DNA methylation of CA10 regulates the \u200dproliferation and metastasis of bladder cancer"],"prefix":"10.3164","volume":"77","author":[{"given":"Qiwang","family":"Mo","sequence":"first","affiliation":[{"name":"Department of Urology, Shengzhou People\u2019s Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Urology, Shengzhou People\u2019s Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jizhongrong","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Urology, Shengzhou People\u2019s Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Shengzhou People\u2019s Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1739","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Comp\u00e9rat E, Amin MB, Cathomas R, et al. Current best practice for bladder cancer: a narrative review of diagnostics and treatments. Lancet 2022; 400: 1712\u20131721.","DOI":"10.1016\/S0140-6736(22)01188-6"},{"key":"2","unstructured":"2 Flaig TW, Spiess PE, Abern M, et al. NCCN Guidelines<sup>\u00ae<\/sup> Insights: Bladder Cancer, Version 2.2022. J Natl Compr Canc Netw 2022; 20: 866\u2013878."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Song Q, Yu H, Cheng Y, et al. Bladder cancer-derived exosomal KRT6B promotes invasion and metastasis by inducing EMT and regulating the immune microenvironment. J Transl Med 2022; 20: 308.","DOI":"10.1186\/s12967-022-03508-2"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Trimarchi MP, Yan P, Groden J, Bundschuh R, Goodfellow PJ. Identification of endometrial cancer methylation features using combined methylation analysis methods. PLoS One 2017; 12: e0173242.","DOI":"10.1371\/journal.pone.0173242"},{"key":"5","unstructured":"5 Stampoliou A, Arapantoni-Dadioti P, Pavlakis K. Epigenetic mechanisms in endometrial cancer. J BUON 2016; 21: 301\u2013306."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Banno K, Yanokura M, Iida M, Masuda K, Aoki D. Carcinogenic mechanisms of endometrial cancer: involvement of genetics and epigenetics. J Obstet Gynaecol Res 2014; 40: 1957\u20131967.","DOI":"10.1111\/jog.12442"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Wentzensen N, Bakkum-Gamez JN, Killian JK, et al. Discovery and validation of methylation markers for endometrial cancer. Int J Cancer 2014; 135: 1860\u20131868.","DOI":"10.1002\/ijc.28843"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Bartosch C, Lopes JM, Jer\u00f3nimo C. Epigenetics in endometrial carcinogenesis\u2014part 1: DNA methylation. Epigenomics 2017; 9: 737\u2013755.","DOI":"10.2217\/epi-2016-0166"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Balch C, Matei DE, Huang TH, Nephew KP. Role of epigenomics in ovarian and endometrial cancers. Epigenomics 2010; 2: 419\u2013447.","DOI":"10.2217\/epi.10.19"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Chen X, Zhang J, Ruan W, et al. Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer. J Clin Invest 2020; 130: 6278\u20136289.","DOI":"10.1172\/JCI139597"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Hentschel AE, Beijert IJ, Bosschieter J, et al. Bladder cancer detection in urine using DNA methylation markers: a technical and prospective preclinical validation. Clin Epigenetics 2022; 14: 19.","DOI":"10.1186\/s13148-022-01240-8"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Li F, Zheng Z, Chen W, et al. Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms. Drug Resist Updat 2023; 68: 100938.","DOI":"10.1016\/j.drup.2023.100938"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Nunes SP, Henrique R, Jer\u00f3nimo C, Paramio JM. DNA methylation as a therapeutic target for bladder cancer. Cells 2020; 9: 1850.","DOI":"10.3390\/cells9081850"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Sharma A, Reutter H, Ellinger J. DNA methylation and bladder cancer: where genotype does not predict phenotype. Curr Genomics 2020; 21: 34\u201336.","DOI":"10.2174\/1389202921666200102163422"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Zhang YW, Zheng Y, Wang JZ, et al. Integrated analysis of DNA methylation and mRNA expression profiling reveals candidate genes associated with cisplatin resistance in non-small cell lung cancer. Epigenetics 2014; 9: 896\u2013909.","DOI":"10.4161\/epi.28601"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Wang ZR, Wei JH, Zhou JC, et al. Validation of DAB2IP methylation and its relative significance in predicting outcome in renal cell carcinoma. Oncotarget 2016; 7: 31508\u201331519.","DOI":"10.18632\/oncotarget.8971"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Pastorekova S, Parkkila S, Pastorek J, Supuran CT. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J Enzyme Inhib Med Chem 2004; 19: 199\u2013229.","DOI":"10.1080\/14756360410001689540"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Chung W, Bondaruk J, Jelinek J, et al. Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments. Cancer Epidemiol Biomarkers Prev 2011; 20: 1483\u20131491.","DOI":"10.1158\/1055-9965.EPI-11-0067"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Siegel EM, Riggs BM, Delmas AL, Koch A, Hakam A, Brown KD. Quantitative DNA methylation analysis of candidate genes in cervical cancer. PLoS One 2015; 10: e0122495.","DOI":"10.1371\/journal.pone.0122495"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Marzese DM, Hoon DS. Emerging technologies for studying DNA methylation for the molecular diagnosis of cancer. Expert Rev Mol Diagn 2015; 15: 647\u2013664.","DOI":"10.1586\/14737159.2015.1027194"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Akhavan-Niaki H, Samadani AA. DNA methylation and cancer development: molecular mechanism. Cell Biochem Biophys 2013; 67: 501\u2013513.","DOI":"10.1007\/s12013-013-9555-2"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Fang Q, Zhang X, Nie Q, Hu J, Zhou S, Wang C. Improved urine DNA methylation panel for early bladder cancer detection. BMC Cancer 2022; 22: 237.","DOI":"10.1186\/s12885-022-09268-y"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Gilyazova I, Enikeeva K, Rafikova G, et al. Epigenetic and immunological features of bladder cancer. Int J Mol Sci 2023; 24: 9854.","DOI":"10.3390\/ijms24129854"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Harsanyi S, Novakova ZV, Bevizova K, Danisovic L, Ziaran S. Biomarkers of bladder cancer: cell-free DNA, epigenetic modifications and non-coding RNAs. Int J Mol Sci 2022; 23: 13206.","DOI":"10.3390\/ijms232113206"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Yu Y, Cao H, Zhang M, Shi F, Wang R, Liu X. Prognostic value of DNA methylation for bladder cancer. Clin Chim Acta 2018; 484: 207\u2013212.","DOI":"10.1016\/j.cca.2018.05.056"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Venturelli S, Berger A, Weiland T, et al. Differential induction of apoptosis and senescence by the DNA methyltransferase inhibitors 5-azacytidine and 5-aza-2&apos;-deoxycytidine in solid tumor cells. Mol Cancer Ther 2013; 12: 2226\u20132236.","DOI":"10.1158\/1535-7163.MCT-13-0137"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Buchi F, Spinelli E, Masala E, et al. Proteomic analysis identifies differentially expressed proteins in AML1\/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine. Leuk Res 2012; 36: 607\u2013618.","DOI":"10.1016\/j.leukres.2011.11.024"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Schmiedel BJ, Ar\u00e9lin V, Gruenebach F, Krusch M, Schmidt SM, Salih HR. Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation. Int J Cancer 2011; 128: 2911\u20132922.","DOI":"10.1002\/ijc.25635"}],"container-title":["Journal of Clinical Biochemistry and Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jcbn\/77\/3\/77_25-49\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T04:08:49Z","timestamp":1761970129000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jcbn\/77\/3\/77_25-49\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.3164\/jcbn.25-49","relation":{},"ISSN":["0912-0009","1880-5086"],"issn-type":[{"type":"print","value":"0912-0009"},{"type":"electronic","value":"1880-5086"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"25-49"}}